Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials

benzinga.com/news/health-care/25/06/45845078/mercks-cholesterol-lowering-drug-hits-primary-goal-in-two-pivotal-trials

Merck & Co., Inc. (NYSE:MRK) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for hyperlipidemia on…

This story appeared on benzinga.com, 2025-06-09 18:15:01.
The Entire Business World on a Single Page. Free to Use →